Skip to main content

Signifor LAR Side Effects

Generic name: pasireotide

Medically reviewed by Drugs.com. Last updated on Oct 22, 2023.

Note: This document contains side effect information about pasireotide. Some dosage forms listed on this page may not apply to the brand name Signifor LAR.

Applies to pasireotide: powder for suspension, solution.

Serious side effects of Signifor LAR

Along with its needed effects, pasireotide (the active ingredient contained in Signifor LAR) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking pasireotide:

More common

Incidence not known

Other side effects of Signifor LAR

Some side effects of pasireotide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to pasireotide: intramuscular powder for injection extended release, subcutaneous solution.

Cardiovascular

Very common (10% or more): Hypertension (10%)

Common (1% to 10%): Hypotension (7%), prolonged QT (6%), sinus bradycardia (6%)[Ref]

Dermatologic

Very common (10% or more): Alopecia (12%)

Common (1% to 10%): Pruritus (8%), dry skin (6%)[Ref]

Endocrine

Common (1% to 10%): Adrenal insufficiency (6%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (58%), nausea (52%), abdominal pain (24%), upper abdominal pain (10%)

Common (1% to 10%): Constipation (7%), vomiting (7%), abdominal distention (6%)[Ref]

General

Very common (10% or more): Asthenia (11%), peripheral edema (10%), decreased appetite (10%)[Ref]

Hematologic

Very common (10% or more): Elevated PTT (47%), elevated PT (33%)

Common (1% to 10%): Anemia[Ref]

Hepatic

Very common (10% or more): Cholelithiasis (30%), alanine aminotransferase increased (10%), gamma-glutamyl transferase increased (10%)

Common (1% to 10%): Aspartate aminotransferase increased (6%)[Ref]

Local

Very common (10% or more): Injection site reactions (17%)[Ref]

Metabolic

Very common (10% or more): Hyperglycemia (40%), diabetes mellitus (18%), glycosylated hemoglobin increased (11%), hypercholesterolemia (10%)

Common (1% to 10%): Hypoglycemia (9%), Type 2 diabetes mellitus (9%), lipase increased (7%), hypokalemia (6%), blood glucose increased (6%), blood amylase increased (2%)[Ref]

Musculoskeletal

Common (1% to 10%): Myalgia (9%), arthralgia (8%), back pain (6%), pain in extremity (6%)[Ref]

Nervous system

Very common (10% or more): Headache (28%), fatigue (19%)

Common (1% to 10%): Dizziness (9%), anxiety (9%), insomnia (9%), vertigo (6%)[Ref]

Respiratory

Very common (10% or more): Nasopharyngitis (13%)

Common (1% to 10%): Influenza (9%)[Ref]

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Signifor (pasireotide). Novartis Pharmaceuticals. 2013.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.